Treatment of Multiple Sclerosis Relapses

Advice for community neurologists: best practices for patient follow-up after receiving therapy, and incorporating new treatment algorithms.

Thomas P. Leist, MD, PhD, provides an overview of the use of repository corticotropic injections in treating patients with relapsed multiple sclerosis.

The role of corticosteroids in treating patients with relapsed multiple sclerosis, and alternative first-line treatments.

An expert neurologist considers how to assess a relapsed patient, the goals of first-line therapy, and the value of administering early treatment.

Thomas P. Leist, MD, PhD, discusses the importance of treating relapsed multiple sclerosis and the new treatment algorithm published at CMSC (Consortium of Multiple Sclerosis Centers).

Dr Berkovich provides final thoughts on barriers to adoption, community advice, and future improvements in outcomes measures in the treatment of MS [multiple sclerosis] relapses.

An age-old scale, EDSS, is examined with its limitations in MS [multiple sclerosis], and major outcomes measures such as MRI imaging are discussed.

Costs are considered in ACTH use as well as the differentiating factor in adverse effects of ACTH versus systemic steroids in relapsing MS treatment.

Regina Berkovich, MD, PhD, highlights the use of ACTH in a second-line or third-line setting in MS relapses and the impact on B lymphocytes.

A breakdown of the ACTH protein is provided in repository corticotropic injection use in relapsing MS.

Corticosteroids as a first-line treatment approach, along with dosing and alternatives to systemic steroids, are explored in MS relapses.

Regina Berkovich, MD, PhD, discusses systemic steroids and approach to diagnosis as factors for the new algorithm in treating MS relapses.
SAP Partner Banner